Literature DB >> 23018580

Psychotherapy for depression among patients with advanced cancer.

Tatsuo Akechi1.   

Abstract

Cancer causes profound suffering for patients, and previous reports have demonstrated that psychological distress, particularly depression, is frequently observed in advanced and/or terminally ill cancer patients. Such depression can lead to serious and far-reaching negative consequences in patients with advanced cancer: reducing their quality of life and causing severe suffering, a desire for early death, and suicide, as well as psychological distress in family members. For the management of their distress, cancer patients are more likely to prefer psychotherapeutic interventions to pharmacotherapy, and psychotherapy is known to be effective for the management of depression among advanced cancer patients. Hence, psychotherapy is an important treatment strategy for alleviating their depression. Furthermore, patients with advanced and/or terminal cancer suffer from various physical symptoms and are forced to face a continuous decline in physical function. In addition, psychological defense mechanisms such as denial are frequently observed in these patients. Hence, an individually tailored and careful psychotherapeutic approach should be followed, which considers the specific nature of the advanced and/or terminal cancer. This review focuses on psychological interventions that can be utilized in the clinical oncology practice to ameliorate depression among advanced and/or terminally ill cancer patients, rather than focusing on the level of evidence for each intervention. In addition, the current review introduces some novel therapeutic strategies that have not yet been proved to be effective but show promise for future studies.

Entities:  

Mesh:

Year:  2012        PMID: 23018580     DOI: 10.1093/jjco/hys152

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

Review 1.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

2.  Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study.

Authors:  Abebe Muche Belete; Anmut Alemagegn; Anemut Tilahun Mulu; Taklo Simeneh Yazie; Bekalu Bewket; Adisu Asefa; Wendimeneh Shibabaw Shiferaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  Psychosocial-spiritual interventions among Muslims undergoing treatment for cancer: an integrative review.

Authors:  Abdallah Abu Khait; Mark Lazenby
Journal:  BMC Palliat Care       Date:  2021-03-29       Impact factor: 3.234

4.  Clinical practice guidelines for the care of psychologically distressed bereaved families who have lost members to physical illness including cancer.

Authors:  Tatsuo Akechi; Yosuke Kubota; Yoichi Ohtake; Noriko Setou; Maiko Fujimori; Emi Takeuchi; Akiko Kurata; Masako Okamura; Hideaki Hasuo; Ryo Sakamoto; Seraki Miyamoto; Mariko Asai; Kumiko Shinozaki; Hideki Onishi; Toshiaki Shinomiya; Toru Okuyama; Yukihiro Sakaguchi; Hiromichi Matsuoka
Journal:  Jpn J Clin Oncol       Date:  2022-05-31       Impact factor: 2.925

5.  Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study.

Authors:  Jonas Kuon; Miriam Blasi; Laura Unsöld; Jeannette Vogt; Anja Mehnert; Bernd Alt-Epping; Birgitt van Oorschot; Jochen Sistermanns; Miriam Ahlborn; Ulrike Ritterbusch; Susanne Stevens; Christoph Kahl; Anne Ruellan; Kathrin Matthias; Thomas Kubin; Kerstin Stahlhut; Andrea Heider; Florian Lordick; Michael Thomas
Journal:  Support Care Cancer       Date:  2021-12-07       Impact factor: 3.359

6.  Brief, manualised and semistructured individual psychotherapy programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial.

Authors:  Seraki Miyamoto; Tadahiro Yamazaki; Ken Shimizu; Toshio Matsubara; Hidenori Kage; Kousuke Watanabe; Hiroshi Kobo; Yutaka Matsuyama; Gary Rodin; Kazuhiro Yoshiuchi
Journal:  BMJ Open       Date:  2022-03-11       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.